M
MetaVia Inc. (MTVA)
NCM – Real Time Price. Currency in USD
1.43
-0.10 (-6.54%)
At close: Jun 26, 2026, 4:00 PM EDT
1.43
+0.00 (0.01%)
After-hours: Jun 26, 2026, 7:44 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.43
-0.10 (-6.54%)
At close: Jun 26, 2026, 4:00 PM EDT
1.43
+0.00 (0.01%)
After-hours: Jun 26, 2026, 7:44 PM EDT
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
| Name | Position |
|---|---|
| Dr. Mi-Kyung Kim | Chief Scientific Officer |
| Dr. W. Christopher Fang M.D. | Consulting Chief Medical Officer & Advisor |
| Mr. Hyung Heon Kim | CEO, President & Director |
| Mr. Marshall H. Woodworth | Chief Financial Officer |
| Mr. Michael C. Pine | Senior Vice President of Business Development Advisor |
| Mr. Robert Homolka | Senior Vice President of Clinical Operations |
| Date | Type | Document |
|---|---|---|
| 2026-06-08 | S-8 | tm2615356d1_s8.htm |
| 2026-06-08 | 8-K | tm2615356d2_8k.htm |
| 2026-05-27 | 8-K | mtva-20260527x8k.htm |
| 2026-05-18 | 8-K | mtva-20260518x8k.htm |
| 2026-05-14 | 8-K | mtva-20260514x8k.htm |
| 2026-05-14 | 10-Q | mtva-20260331x10q.htm |
| 2026-05-11 | 8-K | mtva-20260511x8k.htm |
| 2026-04-27 | DEF 14A | ny20067174x2_def14a.htm |
| 2026-04-27 | ARS | ny20067174x3_ars.pdf |
| 2026-04-15 | PRE 14A | ny20067174x1_pre14a.htm |